SCHEMBL4675422

SCHEMBL4675422

O=C(C=C(O)c1nc[nH]n1)c1cocc1Oc1ccccc1C(F)(F)F

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.33
RXRB P28702 1/20 0.33
RXRG P48443 1/20 0.33
NOTUM Q6P988 1/20 0.32
MRGPRX4 Q96LA9 1/20 0.32
MAOB P27338 1/20 0.32
NFE2L2 Q16236 1/20 0.31
PPARG P37231 1/20 0.31
FAAH O00519 1/20 0.31
BCHE P06276 1/20 0.31
ACHE P22303 1/20 0.31
P2RY1 P47900 1/20 0.31
RORC P51449 1/20 0.31
THRA P10827 1/20 0.31
THRB P10828 1/20 0.31
STK39 Q9UEW8 1/20 0.31
MCL1 Q07820 1/20 0.31
HTR1A P08908 1/20 0.30
SLC6A2 P23975 1/20 0.30
SLC6A4 P31645 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4676769 0.85 CXCL8 (0.36)
SCHEMBL4675284 0.85 HTT (0.40)
SCHEMBL4673539 0.84 CTNNB1 (0.33)
SCHEMBL4674286 0.83 RXRA (0.33) RXRARXRBRXRGNOTUMMRGPRX4
SCHEMBL4674602 0.83 ALDH1A1 (0.34)
SCHEMBL4670704 0.82 RXRA (0.33) RXRARXRBRXRGNOTUMMRGPRX4
SCHEMBL4671054 0.82 KDM4E (0.34) NOTUM
SCHEMBL4676929 0.82 KDM4E (0.38) MRGPRX4P2RY1THRATHRB
SCHEMBL4673188 0.81 AR (0.36) MAOBPPARGSLC6A2SLC6A4
SCHEMBL4679125 0.80 MRGPRX4 (0.37) RXRARXRBRXRGNOTUMMRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 RXRA 1268/4885RXRB 1235/4885RXRG 2172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.